These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 25205666)
1. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. Fox AD; Chamberlain A; Sohler NL; Frost T; Cunningham CO J Subst Abuse Treat; 2015 Jan; 48(1):112-6. PubMed ID: 25205666 [TBL] [Abstract][Full Text] [Related]
2. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program. Shah PA; Sohler NL; López C; Fox AD; Cunningham CO J Opioid Manag; 2013; 9(6):407-13. PubMed ID: 24481929 [TBL] [Abstract][Full Text] [Related]
3. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications. Bruce RD; Dvoryak S; Sylla L; Altice FL Int J Drug Policy; 2007 Aug; 18(4):326-8. PubMed ID: 17689382 [TBL] [Abstract][Full Text] [Related]
4. Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment. Fox AD; Chamberlain A; Frost T; Cunningham CO Subst Abus; 2015; 36(2):155-60. PubMed ID: 25837290 [TBL] [Abstract][Full Text] [Related]
5. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434 [TBL] [Abstract][Full Text] [Related]
6. Consumer attitudes about opioid addiction treatment: a focus group study in New York City. Sohler NL; Weiss L; Egan JE; López CM; Favaro J; Cordero R; Cunningham CO J Opioid Manag; 2013; 9(2):111-9. PubMed ID: 23709320 [TBL] [Abstract][Full Text] [Related]
7. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182 [TBL] [Abstract][Full Text] [Related]
8. Use and misuse of opioid replacement therapies: a Queensland study. Smirnov A; Kemp R Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993 [TBL] [Abstract][Full Text] [Related]
9. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. Stancliff S; Joseph H; Fong C; Furst T; Comer SD; Roux P J Addict Dis; 2012; 31(3):278-87. PubMed ID: 22873189 [TBL] [Abstract][Full Text] [Related]
10. Buprenorphine in the United States: Motives for abuse, misuse, and diversion. Chilcoat HD; Amick HR; Sherwood MR; Dunn KE J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979 [TBL] [Abstract][Full Text] [Related]
11. "They're making it so hard for people to get help:" Motivations for non-prescribed buprenorphine use in a time of treatment expansion. McLean K; Kavanaugh PR Int J Drug Policy; 2019 Sep; 71():118-124. PubMed ID: 31330267 [TBL] [Abstract][Full Text] [Related]
12. I heard about it from a friend: assessing interest in buprenorphine treatment. Fox AD; Shah PA; Sohler NL; Lopez CM; Starrels JL; Cunningham CO Subst Abus; 2014; 35(1):74-9. PubMed ID: 24588297 [TBL] [Abstract][Full Text] [Related]
13. Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults. Peck KR; Ochalek TA; Badger GJ; Sigmon SC Drug Alcohol Depend; 2020 Mar; 208():107879. PubMed ID: 31991327 [TBL] [Abstract][Full Text] [Related]
14. Initial experience with subcutaneous depot buprenorphine in a medically supervised injecting facility. Weeks A; Cogger S; Clark N Drug Alcohol Rev; 2021 Nov; 40(7):1354-1355. PubMed ID: 33821545 [No Abstract] [Full Text] [Related]
15. Effectiveness of buprenorphine maintenance treatment as compared to a syringe exchange program among buprenorphine misusing opioid-dependent patients. Aalto M; Visapää JP; Halme JT; Fabritius C; Salaspuro M Nord J Psychiatry; 2011 Sep; 65(4):238-43. PubMed ID: 21047194 [TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of a community-based buprenorphine treatment intervention. Fox AD; Sohler NL; Frost T; Lopez C; Cunningham CO Harm Reduct J; 2017 May; 14(1):23. PubMed ID: 28499432 [TBL] [Abstract][Full Text] [Related]
17. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington. Hood JE; Banta-Green CJ; Duchin JS; Breuner J; Dell W; Finegood B; Glick SN; Hamblin M; Holcomb S; Mosse D; Oliphant-Wells T; Shim MM Subst Abus; 2020; 41(3):356-364. PubMed ID: 31403907 [No Abstract] [Full Text] [Related]
18. The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants. Hall OT; Entrup P; Farabee K; Qin H; Rizvi H; Rausch J; Felkel WC; Teater J Subst Use Misuse; 2024; 59(2):312-315. PubMed ID: 37861246 [No Abstract] [Full Text] [Related]
19. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. Wang L; Weiss J; Ryan EB; Waldman J; Rubin S; Griffin JL J Subst Abuse Treat; 2021 May; 124():108272. PubMed ID: 33771276 [TBL] [Abstract][Full Text] [Related]
20. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]